News Stories

OET awarded Innovate UK grant for Covid-19 vaccine development

Government funding announced for Oxford biotech company to work with leading Australian vaccine company on the development of a new and innovative Covid 19 vaccine.   A grant from Innovate UK, part of UK Research and Innovation, has been made to support a partnership between Vaxine Pty Ltd  (http://vaxine.net) who developed the world’s first swine flu vaccine in 2009, and Oxford Expression Technologies (https://oetltd.com). This Innovate UK grant endorses the

SARS-CoV-2 (COVID-19 Virus) Research

OET is currently helping COVID-19 research efforts by producing the recombinant spike glycoprotein of SARS-CoV-2 for clients. The protein will be used for further research, diagnostics and potential vaccine production. OET is also engaged in in-house COVID-19 research and is working on an insect cell-based vaccine using our flashBAC system enabled through funding from Innovate UK/Department of Health through the Vaccines for Global Epidemics:development and manufacture initiative. OET has recently received further

Expression Systems Media

Expression Systems Insect Cell Culture Media OET is pleased to offer a wide range of Expression Systems Insect cell culture media, from the very popular ESF 921, to specialized insect transfection media. Expression Systems’ media are easy to adapt your cells into and the insect specific media gives great protein yield, when compared to rival media. ESF 921 Insect Culture Media OET use ESF 921 for all in-house work, due